Skip to main content

Table 3 Subgroup analysis of included RCTs in meta-analysis

From: Effect of omega-3 supplementation on lipid profile in children and adolescents: a systematic review and meta-analysis of randomized clinical trials

Variable

Age

Study design

Trial duration

Study Population

 

TG

> 13 years

≤ 13 years

Parallel

Cross over

≥ 6 months

< 6months

E

N

H

No. of comparison

7

7

12

2

7

7

3

8

3

WMD (95% CI)

-5.59(-12.58, 1.40)

-25.09(-43.29, -6.90)

-12.95(-22.88, -3.01)

-63.36(-123.18, -3.55)

-9.63(-15.94, -3.33)

-23.41(-41.37, -5.46)

-25.98(-69.35, 17.40)

-12.18(-25.19, 0.82)

-28.26(-39.12, -17.41)

p value

0.117

0.007

0.011

0.038

0.003

0.011

0.240

0.066

0.000

I2 (%)

57.2

84.6

88.7

63.6

0.0

94

78.5

90.1

0.0

p-heterogeneity

0.029

0.000

0.000

0.097

0.981

0.000

0.010

0.000

0.934

HDL

> 13 years

≤ 13 years

Parallel

Cross over

≥ 6 months

< 6months

E

N

H

No. of comparison

7

5

10

2

5

7

3

6

3

WMD (95% CI)

1.89 (-0.61, 4.38)

-0.06 (-3.82, 3.70)

0.92 (-1.02, 2.86)

5.72 (-8.40, 19.84)

3.13(0.20, 6.07)

-0.71(-2.67, 1.24)

4.62 (-6.40, 16.84)

-2.02(-2.97, 0.71)

-1.04 (-3.74, 1.66)

p value

0.138

0.974

0.352

0.428

0.036

0.473

0.211

0.443

0.451

I2 (%)

88.7

78.3

88.7

52.7

75.6

75.4

64.6

82.3

0.0

p-heterogeneity

0.000

0.001

0.000

0.146

0.003

0.000

0.059

0.000

0.926

LDL

> 13 years

≤ 13 years

Parallel

Cross over

≥ 6 months

< 6months

E

N

H

No. of comparison

7

1

7

1

4

4

2

4

2

WMD (95% CI)

1.94 (-2.75, 6.64)

3.70(-7.64, 15.04)

0.92 (-3.24, 5.07)

8.02 (-1.12, 17.16)

3.18(-3.39, 9.74)

1.52 (-4.67, 7.71)

-2.71(-14.55, 9.13)

2.21(-3.25, 7.67)

8.15 (-0.37, 16.67)

p value

0.417

0.523

0.665

0.085

0.343

0.631

0.654

0.428

0.061

I2 (%)

48.3

0.0

34.2

0.0

6.1

62.4

60.2

43.1

0.0

p-heterogeneity

0.071

-

0.167

-

0.363

0.047

0.113

0.153

0.939

TC

> 13 years

≤ 13 years

Parallel

Cross over

≥ 6 months

< 6months

E

N

H

No. of comparison

7

5

10

2

5

7

3

6

3

WMD (95% CI)

-2.09(-14.67, 10.49)

-0.68(-9.83, 8.48)

-1.64(-10.21, 6.94)

0.55(-10.83, 11.92)

3.84(-1.98, 9.67)

-5.43(-17.04, 6.19)

-11.62 (-48.48, 25.24)

1.99 (-4.78, 8.77)

-0.76(-7.60, 6.09)

p value

0.745

0.885

0.708

0.925

0.196

0.360

0.537

0.564

0.828

I2 (%)

93.3

65.4

91.4

0.0

0.0

94.1

94.3

78.2

0.0

p-heterogeneity

0.000

0.021

0.000

0.797

0.725

0.000

0.000

0.000

0.796

  1. TC total cholesterol, TG triglyceride, HDL high density lipoprotein, LDL low density lipoprotein, H hyperlipidemia, N: includes patients with NAFLD, obesity and metabolic syndrome; E: Includes patients with migraine or hemodialysis or hyperphenyl alaninemia or methylmalonic acidemia
Back to article page

Nutrition Journal

ISSN: 1475-2891

Contact us